Serum response factor induces epithelial to mesenchymal transition with resistance to sorafenib in hepatocellular carcinoma

International Journal of Oncology

Volumn 44, Issue 1, 2014, Pages 129-136

  Bae, Jun Sang ^a   Noh, Sang Jae ^a   Kim, Kyoung Min ^a   Jang, Kyu Yun ^a   Chung, Myoung Ja ^a   Kim, Dae Gohn ^b   Moon, Woo Sung ^a  

^a Chonbuk National University   (South Korea)

^b Jeonbuk National University Medical School and Hospital   (South Korea)

Author keywords

Carcinoma; Chemoresistance; Hepatocellular; Serum response factor

Indexed keywords

SERUM RESPONSE FACTOR; SORAFENIB; TRANSCRIPTION FACTOR SNAIL; UVOMORULIN;

ADULT; APOPTOSIS; ARTICLE; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; SERUM RESPONSE FACTOR; VIMENTIN;

EID: 84891930752     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2154     Document Type: Article

References (42)

1. El-Serag HB: Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142: 1264-1273, 2012.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
3. Avila MA, Berasain C, Sangro B and Prieto J: New therapies for hepatocellular carcinoma. Oncogene 25: 3866-3884, 2006.
4. Polyak K and Weinberg RA: Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9: 265-273, 2009.
5. Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428, 2009.
6. Creighton CJ, Li X, Landis M, et al: Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 106: 13820-13825, 2009.
7. Singh A and Settleman J: EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29: 4741-4751, 2010.
8. Kurrey NK, Jalgaonkar SP, Joglekar AV, et al: Snail and slug mediate radioresistance and chemoresistance by antagonizing P53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 27: 2059-2068, 2009.
9. Wang Z, Li Y, Kong D, et al: Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 69: 2400-2407, 2009.
10. Peinado H, Olmeda D and Cano A: Snail, ZEB and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7: 415-428, 2007.
11. Treisman R: Identification of a protein-binding site that mediates transcriptional response of the c-fos gene to serum factors. Cell 46: 567-574, 1986.
12. Treisman R: Identification and purification of a polypeptide that binds to the c-fos serum response element. EMBO J 6: 2711-2717, 1987.
13. Shore P and Sharrocks AD: The MADS-box family of transcription factors. Eur J Biochem 229: 1-3, 1995.
14. Modak C and Chai J: Serum response factor: look into the gut. World J Gastroenterol 16: 2195-2201, 2010.
15. Miano JM: Role of serum response factor in the pathogenesis of disease. Lab Invest 90: 1274-1284, 2010.
16. Psichari E, Balmain A, Plows D, Zoumpourlis V and Pintzas A: High activity of serum response factor in the mesenchymal transition of epithelial tumor cells is regulated by RhoA signaling. J Biol Chem 277: 29490-29495, 2002.
17. Park MY, Kim KR, Park HS, et al: Expression of the serum response factor in hepatocellular carcinoma: Implications for epithelial-mesenchymal transition. Int J Oncol 31: 1309-1315, 2007.
18. Kwon CY, Kim KR, Choi HN, et al: The role of serum response factor in hepatocellular carcinoma: Implications for disease progression. Int J Oncol 37: 837-844, 2010.
19. Choi HN, Kim KR, Lee JH, et al: Serum response factor enhances liver metastasis of colorectal carcinoma via alteration of the E-cadherin/β- catenin complex. Oncol Rep 21: 57-63, 2009.
20. Farra R, Dapas B, Pozzato G, et al: Serum response factor depletion affects the proliferation of the hepatocellular carcinoma cells HepG2 and JHH6. Biochimie 92: 455-463, 2010.
21. Wilhelm S, Carter C, Lynch M, et al: Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5: 835-844, 2006.
22. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM and Lynch M: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7: 3129-3140, 2008.
23. Kane RC, Farrell AT, Madabushi R, et al: Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist 14: 95-100, 2009.
24. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th edition. Springer, New York, NY, 2010.
25. Kim DG, Park SY, Kim H, Chun YH, Moon WS and Park SH: A comprehensive karyotypic analysis on a newly established sarcomatoid hepatocellular carcinoma cell line SH-J1 by comparative genomic hybridization and chromosome painting. Cancer Genet Cytogenet 132: 120-124, 2002.
26. Bae JS, Choi HN, Noh SJ, et al: Expression of K19 and K7 in dysplastic nodules and hepatocellular carcinoma. Oncol Lett 4: 213-220, 2012.
27. Kim KR, Choi HN, Lee HJ, et al: A peroxisome proliferator-activated receptor γ antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma. Oncol Rep 18: 825-832, 2007.
28. Cano A, Pérez-Moreno MA, Rodrigo I, et al: The transcription factor Snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2: 76-83, 2000.
29. Park SY, Jang KY, Kim YN, et al: Expression and prognostic significance of serum response factor in cholangiocarcinoma. Korean J Pathol 43: 517-522, 2009.
30. Kim KR, Bae JS, Choi HN, et al: The role of serum response factor in hepatocellular carcinoma: An association with matrix metalloproteinase. Oncol Rep 26: 1567-1572, 2011.
31. Gauthier A and Ho M: Role of sorafenib in the treatment of advanced hepatocellular carcinoma: an update. Hepatol Res 43: 147-154, 2013.
32. Kajiyama H, Shibata K, Terauchi M, et al: Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol 31: 277-283, 2007.
33. Yang AD, Fan F, Camp ER, et al: Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 12: 4147-4153, 2006.
34. Rho JK, Choi YJ, Lee JK, et al: Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer 63: 219-226, 2009.
35. Van Malenstein H, Dekervel J, Verslype C, et al: Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to- mesenchymal transition, increased invasion and risk of rebound growth. Cancer Lett 329: 74-83, 2013.
36. Huang XY, Ke AW, Shi GM, et al: αB-crystallin complexes with 14-3-3ζ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma. Hepatology 57: 2235-2247, 2013.
37. Nagai T, Arao T, Furuta K, et al: Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma. Mol Cancer Ther 10: 169-177, 2011.
38. 388 enhances prostate cancer progression via extracellular signal-related kinase and serum response factor signaling. Clin Cancer Res 17: 4355-4366, 2011.
39. Prencipe M, Madden SF, O'Neill A, et al: Identification of transcription factors associated with castration-resistance: is the serum responsive factor a potential therapeutic target? Prostate 73: 743-753, 2013.
40. Pérez-Saborido B, de los Galanes SJ, Menéu-Díaz JC, et al: Tumor recurrence after liver transplantation for hepatocellular carcinoma: recurrence pathway and prognostic factors. Transplant Proc 39: 2304-2307, 2007.
41. Medjkane S, Perez-Sanchez C, Gaggioli C, Sahai E and Treisman R: Myocardin-related transcription factors and SRF are required for cytoskeletal dynamics and experimental metastasis. Nat Cell Biol 11: 257-268, 2009.
42. Bai S, Nasser MW, Wang B, et al: MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem 284: 32015-32027, 2009.